In the heart of Indian capital city New Delhi, dozens of HIV positive patients have been participating in a sit-in for a month right outside the offices of the National AIDS Control Organization or NACO.

The Chinese company producing Azvudone claimed that 40% of COVID-19 patients administered the drug for more than a week during the third phase of the clinical trial showed improvements when it came to symptoms